Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.
暂无分享,去创建一个
[1] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Norman,et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials , 2005, British Journal of Cancer.
[3] Helmut Friess,et al. Role of Mononuclear Cells and Inflammatory Cytokines in Pancreatic Cancer-Related Cachexia , 2005, Clinical Cancer Research.
[4] E. Felekouras,et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study , 2005, Investigational New Drugs.
[5] J. Furuse,et al. A phase II study of S-1 in patients with metastatic pancreatic cancer , 2005 .
[6] Y. Ikeda,et al. The impact of preoperative serum C‐reactive protein on the prognosis of patients with hepatocellular carcinoma , 2005, Cancer.
[7] J. Bartlett,et al. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder , 2005, British Journal of Cancer.
[8] K. Syrigos,et al. Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study , 2005, Cancer investigation.
[9] A. Manni,et al. Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer , 2004, Oncology.
[10] D. McMillan,et al. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer , 2004, British Journal of Cancer.
[11] B. Kahle,et al. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase , 2004, British Journal of Cancer.
[12] T. Okusaka,et al. Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer , 2004 .
[13] F. Gay,et al. Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: A phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] H. Burris,et al. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Wolff,et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Cosimo,et al. Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma , 2004, Cancer.
[17] M. Reni,et al. Salvage Chemotherapy with Mitomycin, Docetaxel, and Irinotecan (MDI Regimen) in Metastatic Pancreatic Adenocarcinoma: A Phase I and II Trial , 2004, Cancer investigation.
[18] S. Natsugoe,et al. Significant Host- and Tumor-Related Factors for Predicting Prognosis in Patients With Esophageal Carcinoma , 2003, Annals of surgery.
[19] R. Parks,et al. Prognostic factors in the palliation of pancreatic cancer. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[20] W. Scheithauer,et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma , 2003, British Journal of Cancer.
[21] K. Perisinakis,et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. , 2003, Clinical and laboratory haematology.
[22] H. Yoshikawa,et al. Clinical implications of serum C‐reactive protein levels in malignant fibrous histiocytoma , 2002, International journal of cancer.
[23] S. Alıcı,et al. Prognostic Factors in Pancreatic Carcinoma: Serum LDH Levels Predict Survival in Metastatic Disease , 2001, American journal of clinical oncology.
[24] P. Homel,et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. , 2001, The oncologist.
[25] H. Ueno,et al. Prognostic Factors in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Systemic Chemotherapy , 2000, Oncology.
[26] D. Huhn,et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma , 2000, Anti-cancer drugs.
[27] K. Fearon,et al. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor , 2000, The British journal of surgery.
[28] D. McMillan,et al. Pancreatic Cancer as a Model: Inflammatory Mediators, Acute-phase Response, and Cancer Cachexia , 1999, World Journal of Surgery.
[29] B. Giovanella,et al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. , 1999, International journal of oncology.
[30] J. Cubiella,et al. Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials , 1999, American Journal of Gastroenterology.
[31] T. Nozoe,et al. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. , 1998, American journal of surgery.
[32] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] K. Aoki,et al. Prognostic Factors in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy , 1996, Pancreas.
[34] J. Ross,et al. Acute‐phase protein response and survival duration of patients with pancreatic cancer , 1995, Cancer.
[35] P. Heinrich,et al. Acute‐phase response of human hepatocytes: Regulation of acute‐phase protein synthesis by interleukin‐6 , 1990, Hepatology.